Kornimate/medical-research-clean huggingface dataset:
virtual human technology for patients with chronic pain

Conditions: Chronic Musculoskeletal Pain

Summary: the experimental study compares three virtual human interviews of patients with chronic musculoskeletal pain: emotional disclosure and brain, emotional disclosure only, basic information control. effects on attitudes and clinical outcomes at 1-month follow-up are assessed.

emotional disclosure about stressors and other private experiences has been found to be helpful for some people with chronic musculoskeletal pain. also, helping patients understand the role of the brain in pain has been helpful. we have developed a virtual human interviewer to help patients talk about their pain and their lives. we will conduct an experimental study to compare the effects of several different types of vh interviews. patients with chronic pain will be randomized to receive one of three vh interviews: emotional disclosure and brain education; emotional disclosure alone; or a control basic pain interview. patients will be assessed at baseline and 1-month follow-up on a range of attitudinal and clinical measures to determine how these different interviews affect outcomes.

Eligibility criteria:
inclusion criteria: * chronic musculoskeletal pain exclusion criteria: * non-english speaking
supporting attendance for facility delivery and infant health

Conditions: HIV; AIDS

Summary: the goal of this proposed intervention study is to increase the proportion of hiv positive and hiv negative pregnant women who deliver in a facility, the proportion of hiv exposed infants (hei) who receive nevirapine (nvp) within 48 hours of delivery, and the proportion of hei who are bled for hiv polymerase chain reaction (pcr) deoxyribonucleic acid (dna) testing within 8 weeks of age.

following a formative phase i, we propose in phase ii to implement a three-group cluster-randomized study to test the effectiveness of short message service (sms) reminders and notifications, \[mobile health or mhealth\] (group 1) and the combined effectiveness of sms reminders/notifications and cash transfers (group 2) compared to the standard prevention of mother-to-child transmission (of hiv)/maternal, neonatal and child health, (pmtct/mnch) practices (group 3).

Eligibility criteria:
inclusion criteria: * known or recently diagnosed hiv-positive in anc or; tested hiv-negative at anc * plans to deliver in facility catchment area * 18 years or older * able and willing to provide consent exclusion criteria: -

Keywords: pmtct mnch
brain responses to contextual influences on drinking decisions

Conditions: Alcohol Drinking

Summary: this study is using functional magnetic resonance imaging (fmri) to examine brain activity associated with making decisions about drinking alcohol in everyday situations, some of which may involve important activities happening the next day. the secondary aims are to determine whether severity of alcohol-related problems is related to brain activity and alcohol choices and to examine how different areas of the brain interact in connected networks.

the overall objective of this study is to examine brain activity associated with making decisions about drinking alcohol in everyday situations, some of which may involve important activities happening the next day. the secondary aims are to determine whether severity of alcohol-related problems is related to brain activity and alcohol choices and to examine how different areas of the brain interact in connected networks. the study involves two testing sessions -- a baseline interview conducted virtually or in-person, and a mri scanning session at university of kansas medical center. participants (n=80, 50% female, age 21-55) are community adults who report drinking alcohol in excess of niaaa-recommended weekly drinking limits (i.e., heavy drinkers who consume 14/7+ drinks per week for men/women). participants will complete hypothetical alcohol purchase tasks during the mri scan with two conditions being examined. a control condition involves a typical drinking situation with no explicit responsibilities. an experimental condition involves a hypothetical situation with important personally-relevant responsibilities the next day (e.g., a presentation at work, an exam, or caregiving responsibilities).

Eligibility criteria:
inclusion criteria: 1. 21-55 years of age; 2. current heavy alcohol drinking in the past three months, as indicated by reporting consumption of 14 or more drinks per week for men or 7 or more drinks per week for women and at least one heavy drinking episode weekly (5+/4+ drinks in a single occasion for males/females); 3. belong to a category with significant responsibilities, such as being currently employed, a current student, or a caregiver with significant responsibilities; 4. speak english; 5. normal or corrected to normal vision and hearing; 6. able to give informed consent. exclusion criteria: 1. currently engaged in treatment or seeking treatment for alcohol-related problems; 2. major psychiatric illness (psychotic disorder, bipolar disorder, post-traumatic stress disorder); 3. diagnostic and statistical manual version-5 substance use disorder (except nicotine); 4. attending any in-person session with a positive breath alcohol concentration (brac \> 0.00%); 5. any contraindications for mri scanning (e.g., metal in body surgically or accidentally including pacemaker, cochlear implants, aneurysm clips, shrapnel, etc.); 6. history of seizures or anti-seizure medication; 7. history of concussion or other significant brain injury; 8. serious medical illness unsuitable for the mri scanner based on best clinical judgment
theory based sms reminders - text's impact on patient attendance

Conditions: Otorhinolaryngologic Diseases; Sleep Disorders; Hearing Disorders

Summary: the project will be done at the ear, nose and throat outpatient department at lovisenberg diakonale hospital (lds) in 2015-2016. about 12% of patients with appointments at the surgical outpatient clinic at lds do not attend their appointment even after receiving both letters and shot message service (sms) reminders. persuasion theory suggests that the sms reminders may be more effective if the text appeals more to the patient's feelings. the project is designed as a randomized controlled trial in which the control group receives the standard text that has neutral content and the intervention group receives a more emotion-based sms reminder. the aim is to determine whether the more emotional text reduces the proportion of patients who do not show up for their scheduled appointment at the surgical outpatient clinic.

studies from norway's health south east (hsø) show that the number of patients who do not attend their scheduled appointments account for 200 000 to 250 000 outpatient consultations each year. for comparison, there are 270,000 patients waiting for treatment. it has thus been recommended that regional health authorities take measures to reduce the number of patients who do not attend their scheduled appointment. this study will evaluate whether short message service (sms) appointment reminders that appeal to the patient's emotions are more effective for reducing non-attendance to scheduled outpatient appointments at the ear, nose, and throat outpatient clinic at lovisenberg diakonale hospital in oslo, norway. the study will be designed as randomized controlled trial in which 2000 patients are randomly assigned to either the intervention group (emotional sms text) or the control group (standard sms text with neutral content). because theory suggests that emotion-based text messages will be more effective reminders, it is hypothesized that they will result in a 50% reduction in the number of patients who do not show for their appointment compared to the control group.

Eligibility criteria:
inclusion criteria: * patients (any diagnosis) with a scheduled clinic appointment at the lds ear, nose and throat surgical clinic or scheduled for polysomnography during the inclusion period. * date of birth on or after 01.01.1935 exclusion criteria: * patients with 2 appointments on the same day, only the first appointment will be included. * patients without a phone number * patients born before 01.01.1935 * included patients will not be included again if they get a new appointment in the inclusion period.

Keywords: appointment reminder attendance no-show
ckd-828 (80/5mg) pharmacokinetic study

Conditions: Hypertension

Summary: a randomized, open-label, single-dose, two-period, two-way, crossover study to compare the pharmacokinetics and safety ckd-828 (fixed dose combination tablet) to coadministration telmisartan and s-amlodipine in health volunteers.


Eligibility criteria:
inclusion criteria: * a healthy volunteer between 20 and 55 years old * more than 50kg and within 20% of ideal body weight * no any congenital or chronic diseases and medical symptom * appropriate for the study from examination(laboratory test, ecg etc.) within 4weeks prior to the first ip administration * signed the informed consent form prior to the study participation. exclusion criteria: * history of relevant hypersensitivity against drug * clinical significant disease or medical history (ex. hepato/cholangio, cardio, endo, hemato, onco, cns etc.) * active liver disease or abnormal laboratory result (ast or alt or total bilirubin \> 1.5\*uln) * sbp \ 150mmhg * dbp \ 100mmhg * creatinine clearance \<80ml/min * a disease(ex.inflammatory intestinal disease, gastric or duodenal ulcer ,hepatic disease history , gastro-intestinal surgery except for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug * the evidence of severe attack or acute disease or surgical intervention within 28 days prior to the first ip administration. * a drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or regular alcohol consumer(more than 21 units/week) or a heavy smoker(more than 10 cigarettes per a day) * taking etc medicine or oriental medicine within 14days or taking otc medicine within 7days prior to the first ip administration * abnormal diet(especially, grapefruit juice within 7 days prior to the first ip administration) that may influence on the absorption, distribution, metabolism and excretion of the drug

Keywords: hypertension ckd-828 telmisartan s-amlodipine pharmacokinetic
glossopharyngeal nerve block for post -tonsillectomy pain relief

Conditions: Analgesia

Summary: the aim of the present study is to evaluate the efficacy and safety of ultra-sound guided submandibular parapharyngeal glossopharyngeal nerve block as regards time for first need of analgesic as a primary outcome as well as pain score, total postoperative analgesic requirement, and incidence of complications as secondary outcomes

tonsillectomy is one of the most frequent surgical procedures performed all over the world that has been identified as being severely painful especially in the adult population. management of post tonsillectomy pain is of paramount importance in order to improve swallowing and enhance oral intake as well as to decrease the risk of dehydration, infection and secondary hemorrhage with a subsequent hastening of recovery. a variety of analgesic regimens have been implemented to alleviate post-tonsillectomy pain, however; no consensus on the ideal analgesic regimen has been yet identified. the ultrasound (us)-guided glossopharyngeal nerve (gpn) block has been acknowledged as a feasible option for providing perioperative analgesia in tonsillectomy patients. it blocks sensory impulses from the posterior third of the tongue, palatine tonsil, and mucous membranes of the mouth and pharynx. conventional techniques for blocking the gpn carry the risk of vascular puncture, inadvertent block of closely adjacent other cranial nerves, with increased probability of local anesthetic toxicity and even upper airway obstruction. recently, a novel, safe, and reproducible us-guided gpn block technique has been introduced by azman et al, which would block the gpn distally, in the tissue plane just next to the pharyngeal wall and relatively far from high risk nearby structures.

Eligibility criteria:
inclusion criteria: * patients classified by the american society of anesthesiologists asa i and ii patients * scheduled for tonsillectomy procedure exclusion criteria: * patients' refusal * history of diabetes mellitus, * cardiac, liver or renal impairment * obstructive sleep apnea syndrome * swallowing difficulty * intake of chronic pain medications or substance abuse * bleeding disorders * hypersensitivity to the used medication
denosumab sequential therapy

Conditions: Osteoporosis

Summary: denosumab is a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. although denosumab has excellent effect to increase bone mass and prevent fracture in freedom study with very low complications, even up to ten years, it's effect is reversible. after holding the drug, circulating denosumab levels fall rapidly, and bone resorption reaching twice baseline levels for about 6 months. how to prevent bone loss after denosumab therapy is an important issue, especially when considering the compliance, persistence, or other comorbidities of the patient. we want to verify if zoledronic acid could be used as a sequential therapy after denosumab to prevent rapid bone loss by randomized clinical trial.

denosumab is a monoclonal antibody directed against the protein rank-l, the principal regulator of osteoclast development. thus, it acts as a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. because it's easily to be used with very low risk of complications, patient has better compliance and persistence of denosumab than bisphosphonates. it's market share increasing very rapidly in taiwan. although denosumab has excellent effect to increase bone mass and prevent fracture in freedom study with very low complications, even up to ten years, it's effect is reversible. after holding the drug, circulating denosumab levels fall rapidly, and bone resorption reaching twice baseline levels for about 6 months. over the first 12 months off therapy, all the bone density gained on treatment is lost4. according to previous meta-analysis study, although the persistence of denosumab therapy is better than bisphosphonates, only 62% patients keep the treatment after two years. we could image how low the persistence is after five-year or ten-year treatment in the real world. how to prevent bone loss after denosumab therapy is an important issue, especially when considering the compliance, persistence, or other comorbidities of the patient. there is only one randomized controlled trial dealing with this problem, although the primary goal of the study is designed to compare the compliance and persistence1. after switching from denosumab to alendronate for one year, bone mineral density does not decrease rapidly, although there is mild elevation of bone turn over marker. we want to verify if zoledronic acid could be used as a sequential therapy after denosumab to prevent rapid bone loss by randomized clinical trial.

Eligibility criteria:
inclusion criteria: 1. postmenopausal women 2. men \>50-year-old 3. after denosumab treatment ≥ 2 years due to osteoporosis exclusion criteria: 1. patientshadeverusedantiosteoporosismedications other than dmab 2. estimated glomerular filtration rate \<35 ml/min. 3. malignancy 4. continuous steroid treatment, hormone therapy or other medical treatment affecting bone metabolism 5. secondary osteoporosis 6. metabolic bone diseases 7. contraindications to zol 8. patients older than 80 years old 9. hypocalcemia

Keywords: osteoporosis denosumab zoledronate bone mineral density
supporting young women's reproductive health by harnessing prosociality among drug shopkeepers

Conditions: Hiv; Contraception

Summary: the goal of the study is to operationalize and test the preliminary impact of providing regular customer feedback from adolescent girls and young women (agyw) to drug shopkeepers on the distribution of contraceptives and hiv self-testing to agyw over 18 months.

the investigators will cross-randomize 120 drug shops enrolled in the parent malkia klabu effectiveness cluster-randomized controlled trial (crct; nct05357144), stratified by crct study arm, to one of three initial conditions: 1. no feedback. agyw customer feedback will be collected, but not shared with the shopkeeper. 2. private feedback. biweekly summarized reports of agyw customer feedback will be given directly to shopkeepers. 3. public feedback: shopkeepers will get biweekly summarized reports of agyw customer feedback, gold stars reflecting the level of agyw customer feedback (e.g., 1-5 star rating) will be placed in the shop in a visible location, and shopkeepers will be invited to an awards ceremony every 6 months to recognize shopkeepers who receive high levels of positive agyw customer feedback. the investigators will phase in the 2 interventions (private and public feedback) on a staggered basis to control for both shop-specific and time-specific trends for the primary outcomes.

Eligibility criteria:
inclusion criteria: * shopkeepers enrolled in the parent crct exclusion criteria: * none

Keywords: drug shops pro-sociality adolescent health hiv self-testing contraception
wearing-off period of pharmacological dilation and anisocoria

Conditions: Anisocoria

Summary: students at the school of medicine greenville will be asked to participate in this study. the aim of this study is to better understand when medical imaging is needed for patients with anisocoria (unequal pupil size). participation in the study includes up to 3 visits over a period of one week. each study visit will last about 30 minutes. at the first visit, participants will be screened for hyperopia using a phoropter, have their intraocular pressures taken using a tono-pen, and have their iridocorneal angle measured using gonioscopy at the ophthalmology clinic. proparacaine hydrochloride 0.5% eye drops will be used to numb the eyes before measuring intraocular pressures and prior to gonio lens exam. participants will also be asked to complete three forms. participants will be asked to return to the clinic on a scheduled day within one week of the screening visit to have their left eye dilated. at this visit, the diameter of the pupil will be measured using a near card in a windowless room with a set light-level. then, the participant will receive one drop of tropicamide in the left eye. after the drops have had time to take effect, which will be about 20-30 minutes later, the diameter of the pupil will be measured again. participants will then be asked to return to the clinic in 3-4 hours. at this time, the diameter of the pupil will be measured again. the third type of eye drop used in this study is 1% pilocarpine. 1 % pilocarpine will briefly constrict the eyes. one drop of 1% pilocarpine will be administered to left eye, and the change in pupillary diameter will be measured, if any. it will take about 10-15 minutes for the 1% pilocarpine to take effect. participants may be required to attend 2 additional 30-minute visits on a third day depending on how their eyes respond to the drops. this study will recruit about 10-15 participants.


Eligibility criteria:
inclusion criteria: * student at the university of south carolina school of medicine greenville * healthy participants * no significant ophthalmological history exclusion criteria: * a history of angle closure glaucoma, any other type of glaucoma * any elevated eye pressure readings * any history of intraocular surgery or procedure. * if the participant is found to be hyperopic to \>+1 diopter, has an intraocular pressure of \> 22 mm hg in either eye, or displays an iridocorneal angle where trabecular meshwork * known allergy to natural rubber latex
oral mucositis in patients undergoing antineoplastic chemotherapy

Conditions: Oral Mucositis

Summary: the purpose of this study was to: 1. to investigate the feasibility of using infrared (ir) thermometer to grade the severity of oral mucositis in patients with multiple myeloma undergoing chemotherapy. 2. to obtain preliminary data on the most optimal method of scoring the severity of oral mucositis by comparing the results obtained using the ir thermometer to the world health organization (who) mucositis grading system and the patient self-assessment questionnaire. 3. to investigate the correlation between the quantitative readings obtained from oral mucosa with the ir thermometer.

several grading systems for oral mucositis are available including those of the world health organization (who), radiation therapy oncology group (rtog), western consortium for cancer nursing research wccnr, and the national cancer institute common toxicity criteria (ncictc) and others however, all of these oral mucositis grading systems rely on visual examination and are therefore subjective and operator-dependent tools and suffer from significant interpersonal variability (6). with the current improvements in medicine and technology, there is definitely a need for a more objective, easy to perform, non-invasive, affordable, quantitative and reproducible tool that is operator-independent to assess the severity of oral mucositis. the introduction of such a tool would greatly improve our ability to compare the oral mucosal toxicity of antineoplastic therapies and the efficacy of various mucoprotective therapies. furthermore, the use of such a tool can be extended to patients undergoing radiation treatment with or without chemotherapy for various malignancies including head and neck cancers.

Eligibility criteria:
inclusion criteria: * multiple myeloma receiving chemotherapy grade 3/4 mucositis exclusion criteria: * women of child bearing potential who are unable to take adequate contraceptive precautions, have + pregnancy test w/in 24 hrs prior to study, pregnant, currently breastfeeding will not be able to participate in the study

Keywords: mucositis
esomeprazole in patients with gastric acid hypersecretory states including idiopathic hypersecretion and zollinger-ellison syndrome

Conditions: Zollinger-Ellison Syndrome

Summary: this research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.


Eligibility criteria:
inclusion criteria: * males or females at least 18 years of age. * diagnosis of zollinger-ellison syndrome or idiopathic hypersecretion exclusion criteria: * pregnant or lactating females * history of drug addiction or alcohol abuse within 12 months prior to screening. * history of intolerance to any proton pump inhibitors or any ingredient in their formulation.

Keywords: gastric acid hypersecretory conditions idiopathic hypersecretion excessive gastric acid secretion
a phase 2 study of cim331 for atopic dermatitis patients

Conditions: Atopic Dermatitis

Summary: to assess the safety, tolerability and efficacy of cim331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy


Eligibility criteria:
inclusion criteria: * ≥18 and ≤65 years of age at the time of consent. * patients with atopic dermatitis * pruritus visual analogue scale (vas) ≥50 mm at the screening and baseline visit * eczema area and severity index (easi) ≥10 at the screening and baseline visit * static investigator's global assessment (siga) score ≥3 at the baseline visit exclusion criteria: * serological evidence of hepatitis b virus or hepatitis c virus infection * known human immunodeficiency virus infection * ongoing treatment with specific or non-specific hyposensitization therapy for ad * treatment with mild or moderately potent topical corticosteroids (tcs) within 1 week prior to randomization * history of infection including skin infection requiring treatment with oral or intravenous (iv) antibiotics, antivirals, or antifungals within 1 week prior to randomization. * evidence of tuberculosis (tb) infection as defined by a positive purified protein derivative (ppd) and/or positive interferon-gamma release assay. * pregnant or lactating women.